# TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)

> **NCT01362361** · PHASE2 · COMPLETED · sponsor: **Martin-Luther-Universität Halle-Wittenberg** · enrollment: 54 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** mFOLFOX6 + BIBF 1120
- **DRUG:** mFOLFOX6+placebo

## Key facts

- **NCT ID:** NCT01362361
- **Lead sponsor:** Martin-Luther-Universität Halle-Wittenberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362361, "TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01362361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*